Media/Policy Watch

Posted on by

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 6 June 2020
[No new, unique, relevant content]

 

BBC
http://www.bbc.co.uk/
Accessed 6 June 2020
[No new, unique, relevant content]

 

The Economist
http://www.economist.com/
Accessed 6 June 2020
The world after covid-19
Jennifer Doudna on how covid-19 is spurring science to accelerate
A change is under way in the respect for scientists, dissemination of research and forms of collaboration
Jun 5th 2020… More than 150 therapeutic or vaccine candidates are now in clinical trials and hundreds more are in pre-clinical development…

Schumpeter
The quest for a vaccine could restore faith in big pharma
The boffins of AstraZeneca are showing the way forward
Jun 5th 2020… Until the coronavirus, the company barely dabbled in the $60bn-a-year vaccine business. Yet now he is leading the effort not just to create a …

 

Financial Times
http://www.ft.com/home/uk
Accessed 6 June 2020
[No new, unique, relevant content]
Bottom of Form

 

Forbes
http://www.forbes.com/
Accessed 6 June 2020
Breaking  |  
Jun 5, 2020
Trump Says U.S. Is ‘Ready To Go’ With 2 Million Coronavirus Vaccines Upon Approval
No vaccine candidate has been approved, but companies have already begun ramping up for production.
By Carlie Porterfield Forbes Staff

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 6 June 2020
Snapshot June 5, 2020
How to Keep the United States in the WHO
If carried out, withdrawing from the WHO would mark one of the most ruinous presidential decisions of modern history—a blow to global health security and to the rule of…
Harold Hongju Koh and Lawrence O. Gostin

 

Foreign Policy
http://foreignpolicy.com/
Accessed 6 June 2020 | [No new, unique, relevant content]
[No new, unique, relevant content]

 

The Guardian
http://www.guardiannews.com/
[No new, unique, relevant content]

 

New Yorker
http://www.newyorker.com/
Accessed 6 June 2020
[No new, unique, relevant content]

 

New York Times
http://www.nytimes.com/
Accessed 6 June 2020
Middle East
G20 Pledges More Than $21 Billion to Fight Coronavirus
The Group of 20 rich and emerging economies has pledged more than $21 billion to fight the coronavirus, the group said early on Saturday.
By Reuters June 5

Asia Pacific
Japan Aims to Have Coronavirus Vaccines in Use by June 2021
Japan aims to put coronavirus vaccines into use by June 2021, the health minister said on Friday, as the country strives to be fully ready to host the Tokyo Olympics, originally planned for this summer but postponed by one year due to the pandemic.
By Reuters June 5

Asia Pacific
Australia’s CSL Says to Help Fund, Make Vaccine Candidate if It Proves Successful
Australia’s biggest biotech firm CSL Ltd said it would help fund the development of a University of Queensland COVID-19 vaccine candidate and if it was successful, could make up to one hundred million doses towards the end of next year.
By Reuters June 4

Europe
AstraZeneca Targets Two Billion Doses, Poor Countries With COVID Vaccine Deals
British drugmaker AstraZeneca has doubled manufacturing capacity for its potential coronavirus vaccine to 2 billion doses in two deals involving Microsoft billionaire Bill Gates that guarantee early supply to lower income countries.
By Reuters

 

Washington Post
https://www.washingtonpost.com/
Accessed 6 June 2020
The biggest challenge for a coronavirus vaccine could be getting countries to share
William Wan and Carolyn Y. Johnson · Health · Jun 4, 2020